Meeting slides
Suggested Readings

Drug utilization review.

Academy of Managed Care Pharmacy.

Long-acting injectables: current perspectives and future promise.

Chaudhary K, Patel MM, Mehta PJ. Crit Rev Ther Drug Carrier Syst. 2019;36(2):137-181.

Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults.

McGowan JP, Fine SM, Vail RM, et al. Baltimore (MD): Johns Hopkins University; 2022.

Lenacapavir as part of a combination regimen in treatment-naïve people with HIV: Week 54 results.

Gupta SK, Sims J, Brinson C, et al. Conference on Retroviruses and Opportunistic Infection. February 12-16, 2022. Abstract 138.

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine.

Johnson K, Sawkin MT. Drugs Context. 2022;11:2021-9-2.

ASHP statement on advocacy as a professional obligation.

Little J, Ortega M, Powell M, Hamm M. Am J Health Syst Pharm. 2019;76(4):251-253.

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Llibre JM, Hung CC, Brinson C, et al. Lancet. 2018;391(10123):839-849.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. 

Overton ET, Richmond G, Rizzardini G, et al. Lancet. 2021;396(10267):1994-2005.

Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. 

Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. N Engl J Med. 2022;386(19):1793-1803.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. 

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

HIV and ischemic heart disease.

Vachiat A, McCutcheon K, Tsabedze N, et al. J Am Coll Cardiol. 2017;69(1):73-82.

Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen versus continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study.

van Wyk J, Ajana F, Bisshop F, et al. Clin Infect Dis. 2020;71(8):1920-1929.

Linked Resources

Clinical Practice Guidelines

Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society–USA panel.

Saag MS, Gandhi RT, Hoy JF, et al. JAMA. 2020;324(16):1651-1669.

Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.

US Department of Health and Human Services 

Patient and Caregiver Resources

AIDSMap Resources

NAM Publications

Resources for persons living with HIV

Centers for Disease Control and Prevention

HIV Resources

National Institutes of Health

Related activities
1.25 ACPE

Applying HIV Advances in Practice

What the Pharmacist Needs to Know

Faculty: Melissa Badowski, PharmD, MPH, FCCP, BCIDP, BCPS; Jennifer Cocohoba, PharmD, MAS
Release: 09/15/2022
Expiration: 09/15/2023